Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

PSI Shares Insights Into Microbiology Data Review

Posted on: 23 Aug 16

PSI CRO, a global full-service contract research organization also known as the #Antibiotic Powerhouse as pronounced by one of many of its infectious diseases customers, announced today that one of their ID medical experts will be presenting at the upcoming World Anti-Microbial Resistance Congress September 8th-9th in Washington DC.

Dr. Cecilia Dignani who is Medical Officer at PSI CRO has always focused her research on infectious diseases and has published more than 30 scientific articles. On day two of the congress, Dr. Dignani will be presenting a “Review of real world challenges with microbiology data in clinical trials of new antibiotics”. Her talk will address the importance of careful selection of microbiology labs, as well as hands-on recommendations from PSI’s antibiotic case studies.

PSI continues to speed up the arrival of novel antibiotics to market through the successful management and on-time delivery of many complex global trials in the areas of CAP/HAP/VAP, cUTI, IAI, skin infections, sepsis, bacteremia and anti-fungals.

The World Anti-Microbial Resistance Congress gathers decision makers from government, funding agencies, pharma, academia, hospitals, labs, and payers to discuss the urgent need for new antibiotics. The 2-day conference presents solutions through key notes, case study presentations and roundtable discussions. PSI will be fully represented during the 2-day exhibition and conference.

About PSI CRO:

PSI is a privately-owned, full-service contract research organization (CRO), operating globally. PSI’s reputation on the market place is that of a no-nonsense CRO, capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI’s global reach supports the operations of clinical trials across multiple countries and continents. PSI is known to be highly selective about the work that they pursue. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover indicative of its commitment to be the best CRO in the world as measured by its customers and its employees. Global headquarters are located in Zug (Zürich), Switzerland at 113a Baarerstrasse 6300.

View source version on

Business Wire

Last updated on: 23/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.